Detection and characterization of a novel subset of CD8 +CD57 + T cells in metastatic melanoma with an incompletely differentiated phenotype

Clinical Cancer Research

Volumn 18, Issue 9, 2012, Pages 2465-2477

  Wu, Richard C ^a,b,c   Liu, Shujuan ^a   Chacon, Jessica A ^a,b   Wu, Sheng ^a   Li, Yufeng ^a,b   Sukhumalchandra, Pariya ^a   Murray, James L ^a   Molldrem, Jeffrey J ^a   Hwu, Patrick ^a,b   Pircher, Hanspeter ^d   Lizée, Gregory ^a,b   Radvanyi, Laszlo G ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD27 ANTIGEN; CD28 ANTIGEN; CD57 ANTIGEN; GAMMA INTERFERON; GRANZYME B; PERFORIN; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; BONE MATURATION; CD8+ T LYMPHOCYTE; CELL INTERACTION; CELL ISOLATION; CELL MATURATION; CELL SELECTION; CONTROLLED STUDY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTIC INFILTRATION; MELANOMA; METASTASIS; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE SUBPOPULATION; TUMOR DIFFERENTIATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD27; ANTIGENS, CD57; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOLOGIC MEMORY; LEUKOCYTES, MONONUCLEAR; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, CYTOTOXIC; TRANSFORMING GROWTH FACTOR BETA1; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84860526522     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-2034     Document Type: Article

References (49)

1. Dolstra H, Preijers F, Van de Wiel-van Kemenade E, Schattenberg A, Galama J, de Witte T. Expansion of CD8+CD57+ T cells after allogeneic BMT is related with a low incidence of relapse and with cytomegalovirus infection. Br J Haematol 1995;90:300-7.
2. Kagi D, Ledermann B, Burki K, Seiler P, Odermattt B, Olsen KJ, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 1994;369:31-7. (Pubitemid 24144352)
3. + CD8 T lymphocytes correlates with reduced viral plasma RNA after primary HIV infection. AIDS 1999;13:891-9.
4. + subsets in acute Epstein-Barr virus infection: comparison with chronic human immunodeficiency virus disease. J Infect Dis 1998;177:1083-7.
5. Ohkawa T, Seki S, Dobashi H, Koike Y, Habu Y, Ami K, et al. Systematic characterization of human CD8+ T cells with natural killer cell markers in comparison with natural killer cells and normal CD8+ T cells. Immunology 2001;103:281-90. (Pubitemid 32626177)
6. + T cells. Immunology 2003;108:211-9.
7. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8+T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002;8:379-85. (Pubitemid 34407033)
8. Hoji A, Connolly NC, Buchanan WG, Rinaldo CR Jr. CD27 and CD57 expression reveals atypical differentiation ofhuman immunodeficiency virus type 1-specific memory CD8+ T cells. Clin Vaccine Immunol 2007;14:74-80.
9. Brenchley JM, Karandikar NJ, Betts MR, Ambrozak DR, Hill BJ, Crotty LE, et al. Expression of CD57 defines replicative senescence and antigen-induced apoptotic death of CD8+ T cells. Blood 2003;101: 2711-20. (Pubitemid 36857634)
10. + T cells is associated with progression to viral disease in HIV-infection. AIDS 2002;16:2001-11.
11. Okada T, Liai T, Kawachi Y, Moroda T, Takii Y, Hatakeyama K, Abo T. Origin of CD57+ T cells which increase at tumour sites in patients with colorectal cancer. Clin Exp Immunol 1995;102:159-66.
12. Kaech SM, Wherry EJ. Heterogeneity and cell-fate decisions in effector andmemory CD8+T cell differentiation during viral infection. Immunity 2007;27:393-405. (Pubitemid 47418674)
13. Casado JG, Soto R, DelaRosa O, Peralbo E, del Carmen-Muñoz- Villanueva M, Rioja L, et al. CD8 T cells expressing NK associated receptors are increased in melanoma patients and display an effector phenotype. Cancer Immunol Immunother 2005;54:1162-71. (Pubitemid 41416948)
14. Akagi J, Baba H. Prognostic value of CD57(+) T lymphocytes in the peripheral blood of patients with advanced gastric cancer. Int J Clin Oncol 2008;13:528-35.
15. +lymphocyte levels may predict outcome in melanoma patients treated with adjuvant interferon-alpha. Anticancer Res 2008;28: 1139-42.
16. + lymphocyte subset in interferon therapy of patients with renal cell carcinoma. Anticancer Res 2002;22:3679-83.
17. + T cells in the peripheral blood and their impaired immune functions in patients with advanced gastric cancer. Oncol Rep 2003;10:1443-8.
18. Bandres E, Merino J, Vazquez B, Inogés S, Moreno C, Subirá ML. The increase of IFN-gamma production through aging correlates with the expanded CD8(+high) CD28(-)CD57(+) subpopulation. Clin Immunol 2000;96:230-5.
19. + T cells with restricted T-cell receptor beta chain variability after bone marrow transplantation. Blood 1994;83:587-95.
20. + T cells closely correlates with CD56 surface expression. J Immunol 2000;164:1148-52.
21. + early effector T cells identified at tumor site in primary and metastatic melanoma. Cancer Res 2010. 70:8378-87.
22. Sallusto F, Geginat J, Lanzavecchia A. Central memory and effector memory T cell subsets: function, generation, and maintenance. Annu Rev Immunol 2004;22:745-63. (Pubitemid 38680440)
23. + T cells differently expressing three cytolytic effector molecules. J Immunol 2006;177:4330-40.
24. Ahmadzadeh M, Rosenberg SA. TGF-beta 1 attenuates the acquisition and expression of effector function by tumor antigen-specific human memory CD8 T cells. J Immunol 2005;174:5215-23. (Pubitemid 40593159)
25. Bennicelli JL, Guerry Dt. Production of multiple cytokines by cultured human melanomas. Exp Dermatol 1993;2:186-90. (Pubitemid 24009476)
26. Derynck R, Jarrett JA, Chen EY, Eaton DH, Bell JR, Assoian RK, et al. Human transforming growth factor-beta complementary DNA sequence and expression in normal and transformed cells. Nature 1985;316:701-5. (Pubitemid 16239342)
27. Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, et al. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer 2007;96:1879-87. (Pubitemid 46912012)
28. Li Y, Liu S, Hernandez J, Vence L, Hwu P, Radvanyi L. MART-1-specific melanoma tumor-infiltrating lymphocytes maintaining CD28 expression have improved survival and expansion capability following antigenic restimulation in vitro. J Immunol 2010;184:452-65.
29. He L, Hakimi J, Salha D, Miron I, Dunn P, Radvanyi L. A sensitive flow cytometry-based cytotoxic T-lymphocyte assay through detection of cleaved caspase 3 in target cells. J Immunol Methods 2005;304:43-59. (Pubitemid 41262219)
30. Sakuishi K, Apetoh L, Sullivan JM, Blazar BR, Kuchroo VK, Anderson AC. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010. 207:2187-94.
31. + T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat Med 2010;16:1147-51.
32. + cells in HIV-infected and uninfected individuals. J Immunol 2006;177:5145-54.
33. Dudley ME, Wunderlich JR, Robbins PF, Yang JC, Hwu P, Schwartzentruber DJ, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002;298:850-4. (Pubitemid 35231542)
34. Bannard O, Kraman M, Fearon DT. Cutting edge: virus-specific CD8+ T cell clones and the maintenance of replicative function during a persistent viral infection. J Immunol 2010;185:7141-5.
35. + T lymphocytes during active, latent, and resolved infection and its relation with CD57. J Immunol 2005;174:6088-94.
36. Morley JK, Batliwalla FM, Hingorani R, Gregersen PK. Oligoclonal CD8+ T cells are preferentially expanded in the CD57+ subset. J Immunol 1995;154:6182-90.
37. Kim YJ, Stringfield TM, Chen Y, Broxmeyer HE. Modulation of cord blood CD8+ T-cell effector differentiation by TGF-beta1 and 4-1BB costimulation. Blood 2005;105:274-81. (Pubitemid 40053093)
38. + T lymphocytes. Inhibition by transforming growth factor-beta. J Immunol 1991;146:3289-97.
39. Willinger T, Freeman T, Herbert M, Hasegawa H, McMichael AJ, Callan MF. Human naive CD8 T cells down-regulate expression of the WNT pathway transcription factors lymphoid enhancer binding factor 1 and transcription factor 7 (T cell factor-1) following antigen encounter in vitro and in vivo. J Immunol 2006;176:1439-46. (Pubitemid 43134286)
40. Lopez-Verges S, Milush JM, Pandey S, York VA, Arakawa-Hoyt J, Pircher H, et al. CD57 defines a functionally distinct population of mature NK cells in the human CD56dimCD16+ NK-cell subset. Blood 2010;116:3865-74.
41. Jungalwala FB. Expression and biological functions of sulfoglucuronyl glycolipids (SGGLs) in the nervous system-a review. Neurochem Res 1994;19:945-57. (Pubitemid 24243329)
42. Cebo C, Dambrouck T, Maes E, Laden C, Strecker G, Michalski JC, et al. Recombinant human interleukins IL-1alpha, IL-1beta, IL-4, IL-6, and IL-7 show different and specific calcium-independent carbohydrate- binding properties. J Biol Chem 2001;276:5685-91.
43. + T cells. Eur J Immunol 2008;38:995-1000.
44. Zhang J, Scordi I, Smyth MJ, Lichtenheld MG. Interleukin 2 receptor signaling regulates the perforin gene through signal transducer and activator of transcription (Stat)5 activation of two enhancers. J Exp Med 1999;190:1297-308.
45. Godin-Ethier J, Pelletier S, Hanafi LA, Gannon PO, Forget MA, Routy JP, et al. Human activated T lymphocytes modulate IDO expression in tumors through Th1/Th2 balance. J Immunol 2009; 183:7752-60.
46. Thomas DA, Massague J. TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance. Cancer Cell 2005;8:369-80. (Pubitemid 41579832)
47. Gorelik L, Flavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells. Nat Med 2001;7:1118-22. (Pubitemid 33010019)
48. + T cells that can be partially reversed by vaccination. J Clin Invest 2010. 120: 157-67.
49. Haas AR, Sun J, Vachani A, Wallace AF, Silverberg M, Kapoor V, et al. Cycloxygenase-2 inhibition augments the efficacy of a cancer vaccine. Clin Cancer Res 2006;12:214-22. (Pubitemid 43166197)